tert-butyl 4-[1-{[4-(2-butynyloxy)phenyl]sulfonyl}-2-(hydroxyamino)-2-oxoethyl]-1-piperidinecarboxylate | 287392-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-[1-{[4-(2-butynyloxy)phenyl]sulfonyl}-2-(hydroxyamino)-2-oxoethyl]-1-piperidinecarboxylate
• 英文别名: Tert-butyl 4-[1-(4-but-2-ynoxyphenyl)sulfonyl-2-(hydroxyamino)-2-oxoethyl]piperidine-1-carboxylate
• CAS: 287392-60-3
• 化学式: C₂₂H₃₀N₂O₇S
• 分子量: 466.555
• InChiKey: OIPBUPNXIUZVDQ-UHFFFAOYSA-N

物化性质

• 熔点：
  80 °C
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[1-{[4-(2-butynyloxy)phenyl]sulfonyl}-2-(hydroxyamino)-2-oxoethyl]-1-piperidinecarboxylate 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以59%的产率得到2-{[4-(2-butynyloxy)phenyl]sulfonyl}-N-hydroxy-2-(4-piperidinyl) acetamide
  参考文献：
  名称：

  Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors

  摘要：

  该公式的化合物可用于治疗由TNF-α介导的疾病状况，例如类风湿性关节炎、骨关节炎、脓毒症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退化性软骨丧失。

  公开号：

  US06340691B1
• 作为产物：
  描述：

  4-but-2-ynyloxybenzenesulfonyl chloride 在 calcium fluoride 、 potassium fluoride 、 sodium hydroxide 、 草酰氯 、 盐酸羟胺 、 sodium hexamethyldisilazane 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 5.5h， 生成 tert-butyl 4-[1-{[4-(2-butynyloxy)phenyl]sulfonyl}-2-(hydroxyamino)-2-oxoethyl]-1-piperidinecarboxylate
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 4-alkynyloxy Phenyl Sulfanyl, Sulfinyl, and Sulfonyl Alkyl Hydroxamates as Tumor Necrosis Factor-α Converting Enzyme and Matrix Metalloproteinase Inhibitors

  摘要：

  A series of 4-alkynyloxy phenyl sulfanyl, sulfinyl and sulfony alkyl and piperidine-4-carboxylic acid hydroxamides were synthesized. Their structure-activity relationships, against tumor necrosis factor-alpha (TACE) and matrix metalloproteinase (NIMP) inhibitor activities, are presented by investigating the oxidation state on sulfur and altering the P1' substituent. The sulfonyl derivatives 20-24 carrying a 4-butynyloxy moiety were selective TACE inhibitors over the MMPs tested. The sulfinyl derivatives showed a preference for a specific oxidation on sulfur as in compounds 25-28. The selectivity over MMPs was also demonstrated in the sulfonyl series. The enhanced cellular activity was achieved upon incorporating a butynyloxy substituent in the piperidene series. Compounds 64 and 65 were potent inhibitors of TNF-alpha release in the mouse at 100 mg/kg po.

  DOI：

  10.1021/jm040086x

文献信息

• Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
  申请人：American Cyanamid Company

  公开号：US06340691B1

  公开（公告）日：2002-01-22

  Compounds of the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  该公式的化合物可用于治疗由TNF-α介导的疾病状况，例如类风湿性关节炎、骨关节炎、脓毒症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退化性软骨丧失。
• US6340691B1
  申请人：——

  公开号：US6340691B1

  公开（公告）日：2002-01-22
• US6825354B2
  申请人：——

  公开号：US6825354B2

  公开（公告）日：2004-11-30
• [EN] ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS<br/>[FR] COMPOSES D'ACIDE HYDROXAMIQUE CONTENANT UN ALCYNYLE COMME INHIBITEURS D'ENZYME TACE
  申请人：AMERICAN CYANAMID CO

  公开号：WO2000044713A1

  公开（公告）日：2000-08-03

  The invention concerns compounds of formula (I) which are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
• [EN] METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE<br/>[FR] METHODE DE TRAITEMENT DE LA POLYKYSTOSE RENALE
  申请人：AMERICAN DYANAMID COMPANY

  公开号：WO2002083112A2

  公开（公告）日：2002-10-24

  The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EGF receptor kinase inhibitor.